Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
R. Khanna,B. Sattin,W. Afif,E. Benchimol,E. Bernard,A. Bitton,B. Bressler,R. Fedorak,Subrata Ghosh,G. Greenberg,J. Marshall,R. Panaccione,E. Seidman,M. Silverberg,A. Steinhart
DOI: https://doi.org/10.1111/apt.12407
2013-09-01
Abstract:Tumour necrosis factor (TNF)‐antagonists have an established role in the treatment of inflammatory bowel diseases (IBDs), however, subtherapeutic drug levels and the formation of anti‐drug antibodies (ADAs) may decrease their efficacy.